Emulate, Inc. today announced the company’s launch with a $12 million Series A financing to commercialize a first-in-kind, automated ‘Organs-on-Chips’ platform that mimics human physiology and diseases, while permitting real-time elucidation of molecular mechanisms of action and toxicity. Emulate’s proprietary … Continued
View, the leader in dynamic glass, today announced it has named Mark Mendenhall as its chief commercial officer. An accomplished executive with more than three decades of innovation and leadership experience in the energy and electronics industries, Mendenhall will be … Continued
View showcased by The Guardian as a Top 10 sustainability innovation. The Guardian
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases … Continued
Selecta Biosciences, Inc.,a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today provided an update on the company’s product development pipeline, revealing its focus on immune tolerance applications of its proprietary Synthetic Vaccine Particle (SVP) … Continued
Selecta Biosciences Inc., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune tolerance treatments, today announced it has entered into an exclusive license with 3SBio for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis. … Continued
Selecta Biosciences, a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, announced today that it has been awarded a $1.25 million grant from the Bill & Melinda Gates Foundation. The grant supports the research by … Continued
Crocus Technology, a leading developer of magnetically enhanced semiconductor technologies and TowerJazz, the global specialty foundry leader, today announce that Crocus’ CTSX magnetic field sensor family has completed qualification. The CTSX magnetic sensor product family includes CTSX100, 200 and 300 … Continued
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced that at BIND’s annual meeting of stockholders held today the company’s stockholders elected Mr. Charles A. Rowland, Jr., CPA, most recently the … Continued
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today that clinical data on its lead drug candidate, BIND-014, were presented at the American Association of Cancer Research (AACR) meeting. The … Continued